Search for: "TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. et al v. CIPLA LTD. et al"
Results 1 - 4
of 4
Sorted by Relevance
|
Sort by Date
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
18 Apr 2008, 2:00 am
: (Spicy IP), India: OPPI recommends timeframe for pre-grant opposition: (Spicy IP), India: Jatropha patents (agri-biotech): (Spicy IP), India & US: Stem cell patents: (Spicy IP), Kenya: GSK presses Kenya to crack down on imports of fake medicines: (Afro-IP), Nigeria: Interview with Director General of NAFDAC - Cracking down on counterfeit drugs: (Afro-IP), EU: No link between parallel trade and reduction in R&D, says AG in Sot. [read post]
11 Jul 2008, 4:30 am
Part I – Spicy IP), India: Discussion of grant of Indian patents to Cipla for Fosamax derivative and Nexium derivative: (Spicy IP), India: Draft National Biotechnology Regulatory Authority Bill: (Spicy IP), Ivory Coast: Ivorians increasingly choose fake medicines on price: (Afro-IP), Mexico: New Mexican medicaments approvals regime: an early report: (IP tango), UK: Leave to appeal refused in trade mark infringement proceedings between Eli Lilly and 8PM Chemist concerning the… [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real… [read post]
